Cancer Clinical Trials

Contact Research Coordinators at (605)322-3228 or (605)322-3018 for more information

• A221101: Glioblastoma Multiforme

Contact Research Coordinators at (605)322-3228 or (605)322-3018 or email medoncresearch@avera.org for more information

• A221101: Glioblastoma Multiforme

Contact Breast Research Coordinators at (605)322-3295 or (605)322-3291 or email breastresearch@avera.org for more information

• A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

• Single Fraction: Lumpectomy followed by intraoperative electron radiation therapy (IOERT) as a single dose of radiation therapy in early stage, node negative, invasive breast cancer
• 201209135: A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant
  Breast Cancer
• HIOB: Hypofractionated Whole-Breast Irradiation preceded by Intra-Operative Radiotherapy with Electrons as anticipated Boost (HIOB)
• Takeda X31025: A Phase 1 Evaluation of the Safety and Tolerability of TAK-128 in Combination with TAK-117 and Paclitaxel in Advanced Solid Tumors
• Tesaro TNE001: A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination with Everolimus in Advanced Ovarian and Breast Cancer

• NSABP B-59/GBG 96-Gepardouze: A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of tezolizumab or Placebo

• Intraoperative Radiation Therapy (IORT) Registry

• S1418/BR006: A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
• OSU-16106/Bazan: Multi-Institution Phase II Trial of Intraoperative Electron Beam Radiotherapy Boost at the Time of Breast Conserving Surgery with Oncoplastic Reconstruction in Women with Early-Stage Breast Cancer
• C3441020: A Phase 2, Non-Randomized, Open Label, Single Arm, Multi-Center Study of Talazoparib for Neoadjuvant Treatment of Germline BRCA 1/2 Mutation Patients with Early Triple-Negative Breast Cancer
• NSABP FB-13: An Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) with Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients with Premenopausal Estrogen-Receptor Positive/HER2-Negative Primary Breast Cancer

Contact Research Coordinators at (605)322-3221 or (605)322-3291 for more information

• GRAIL: The Circulating Cell-free Genome Atlas (CCGA) Study

Contact Research Coordinators at (605)322-3221 or (605)322-3291 for more information

• GRAIL: The Circulating Cell-free Genome Atlas (CCGA) Study

Contact Research Coordinators at (605)322-3228 or (605)322-3018 or email medoncresearch@avera.org for more information

• GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
• A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer)
• eFT508-0010: eFT508 in Combination with PD-1/PD-L1 Inhibitor Therapy “A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone

Contact Research Coordinators at (605)322-3228 or (605)322-3291 for more information

• SWOG S1400:Squamous Cell Lung Cancer
• CCD002: Identifying Molecular Drivers of Cancer

• I-PREDICT: An open label navigational Investigation of molecular Profile-Related Evidence Determining Individualized Cancer Therapy for patients with incurable malignancies and poor prognoses.

• GRAIL: The Circulating Cell-free Genome Atlas (CCGA) Study
• Tesaro TNE001: A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination with Everolimus in Advanced Ovarian and Breast Cancer
• Takeda X31025: A Phase 1 Evaluation of the Safety and Tolerability of TAK-128 in Combination with TAK-117 and Paclitaxel in Advanced Solid Tumors
• eFT508-0010: eFT508 in Combination with PD-1/PD-L1 Inhibitor Therapy “A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone

Contact Research Coordinators at (605)322-7536 or (605)322-7554 or email gynresearch@avera.org for more information

• GOG 0263: Stage I/IIA Cervical Cancer
• GOG 0264: Sex Cord-Stromal Tumors of the Ovary
• GSB: Gynecologic Specimen Bank for Genetic and Genomic Investigation
• Takeda X31025: A Phase 1 Evaluation of the Safety and Tolerability of TAK-128 in Combination with TAK-117 and Paclitaxel in Advanced Solid Tumors
• Tesaro TNE001: A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination with Everolimus in Advanced Ovarian and Breast Cancer
• CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
• NRG-GY009: A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian
• 3000-03-005/ENGot-OV44: The FIRST: A randomized, Double-Blind, Phase 3 comparison of platinum-based therapy with TSR 042 and niraparib versus standard of care platinum-based therapy as First line treatment of stage III or IV nonmucinous Epithelial ovarian cancer
• NRG-GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
• NRG-GY016: A Phase II Study of MK-3475 Pembrolizumab+Epacadostat in Recurrent Clear Cell Carcinoma of the Ovary

Contact Research Coordinators at (605)322-3086 or (605)322-3018 or email hemresearch@avera.org for more information

Contact Research Coordinators at (605)322-3228 or (605)322-3018 or email medoncresearch@avera.org for more information

• Alchemist: Genetic Testing in Screening Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery

• Anvil: Nivolumab after surgery and chemotherapy in treating patients with stage IB-IIIA non-small cell lung cancer

• S1400: Phase II/III Biomarker-Driven Master Protocol
  for Second Line Therapy of Squamous Cell Lung Cancer
• WIN001:Survival Prolongation by Rationale INnovative Genomics (SPRING): A proof of concept study to explore safety and efficacy of tri-therapy approach in advanced/metastatic NSCLC and retrospectively assess the ability of integrated genomics and transcriptomics to match patients to the combination
• AM0010-201: CYPRESS-1: A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression
• eFT508-0010: eFT508 in Combination with PD-1/PD-L1 Inhibitor Therapy “A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone

Contact Research Coordinators at (605)322-3086 or (605)322-3018 or email hemresearch@avera.org for more information

• UTX-TGR-205: Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma
• A051301: Testing the Addition of the Oral Medication Ibrutinib to Autologous Stem Cell Transplantation for Patients with Relapsed Diffuse Large B-Cell Lymphoma
• PCYC-1141-CA: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
• DB102-02: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1
• eFT508-0010: eFT508 in Combination with PD-1/PD-L1 Inhibitor Therapy “A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone

Contact Research Coordinators at (605)322-3228 or (605)322-3018 or email medoncresearch@avera.org for more information.

• EA6134: Advanced BRAFV600 Mutant Melanom
• eFT508-0010: eFT508 in Combination with PD-1/PD-L1 Inhibitor Therapy “A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone

Contact Research Coordinators at (605)322-3086 or (605)322-3018 or email hemresearch@avera.org for more information

• Takeda C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen
• M13-367: A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Multiple Myeloma

Contact Research Coordinators at (605)322-3086 or (605)322-3018 or email hemresearch@avera.org for more information

Contact Research Coordinators at (605)322-3086 or (605)322-3018 or email hemresearch@avera.org for more information

• Ace-536-MF-001: A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia with and without Red Blood Cell-Transfusion Dependence
  

Contact Research Coordinators at (605)322-3228 or (605)322-3018 or email medoncresearch@avera.org for more information

• A021501: Preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas
• CanStem111P: A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma

Contact Research Coordinators at (605)322-3228 or (605)322-3018 or email medoncresearch@avera.org for more information

• NRG-GU002: Testing if radiation, hormone therapy, and docetaxel versus radiation and hormone therapy after prostectomy decreases cancer recurrence

Contact Research Coordinators at (605)322-3228 or (605)322-3018 or email medoncresearch@avera.org for more information

• eFT508-0010: eFT508 in Combination with PD-1/PD-L1 Inhibitor Therapy “A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone

Contact Research Coordinators at (605)322-3228 or (605)322-3018 or email medoncresearch@avera.org for more information.

Contact Research Coordinator at (605)322-3016 for more information.

• Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation with Unrelated Donors

Contact Research Coordinators at (605)322-3086 or (605)322-3291 for more information

• S1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

Contact Research Coordinators at (605)322-3228 or (605)322-3295 or email medoncresearch@avera.org for more information

• A221101: Glioblastoma Multiforme
• Psychosocial Effects from Breast Cancer Surgery

Contact Research Coordinators at (605)322-3086 or (605)322-3295 or (605)322-3018 or (605)322-3295 for more information

• BCCR: Development and Implementation of the Breast Cancer Collaborative Registry

• NHLBI-MDS: The National Myelodysplastic Syndromes (MDS) Study is for Patients who have persistent unexplained low blood counts, circulating peripheral blasts, or have been recently diagnosed with MDS in the last 6 months and have not received treatment

• TCCR: Thyroid Tumor and Cancer Collaborative Registry (TCCR)